Very exciting mouse results for Leronlimab. We just need similar human results to gain the oncological and financial impetus necessary to save lives and reward the investors. This is coming.
Please keep Burger and Pestell on the clinical side of working with Leronlimab and well away from management and managerial decisions. The path set out and that we are traversing by Dr. JL is a good one that'll reward everyone: management, clinicians and investors fairly.